





CORRECTION OPEN



# Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma

Patience Odeniyide , Marielle E. Yohe, Kai Pollard, Angelina V. Vaseva, Ana Calizo, Lindy Zhang, Fausto J. Rodriguez , John M. Gross, Amy N. Allen, Xiaolin Wan, Romel Somwar, Karisa C. Schreck , Linda Kessler, Jiawan Wang and Christine A. Pratilas 

© The Author(s) 2022

*Oncogene* (2022) 41:3037; <https://doi.org/10.1038/s41388-022-02342-6>

Correction to: *Oncogene* <https://doi.org/10.1038/s41388-022-02305-x>, published online 22 April 2022

Following the publication of this article a number of copy editing omissions were noted.

These have now been corrected.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022